文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

亚段肺栓塞抗凝与不抗凝患者结局的系统评价与Meta分析

Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment.
PubMed 文献 · Acad Emerg Med · 2018-05-08
一句话结论系统评价与Meta分析提示,亚段肺栓塞患者抗凝与不抗凝的静脉血栓栓塞复发和死亡汇总率无增加,但证据受小样本、不精确和缺乏对照试验限制,作者认为存在临床均势。

该系统评价检索了Ovid MEDLINE、PubMed、Embase、Cochrane Library、Scopus、Web of Science、ClinicalTrials.gov、Google Scholar及参考文献,时间至2017年3月,纳入14项研究共15,563例患者。汇总数据显示异质性I2=99%、Egger检验P<0.001,提示显著发表偏倚;亚段肺栓塞汇总患病率为4.6%(95%CI 1.8%-8.5%)。抗凝组出血频率为8.1%(95%CI 2.8%-15.8%,n=589),未治疗组无出血数据(n=126);90天内VTE复发抗凝组5.3%(95%CI 1.6%-10.9%) vs 未抗凝组3.9%(95%CI 4.8%-13.4%),死亡抗凝组2.1%(95%CI 3.4%-5.2%) vs 未抗凝组3.0%(95%CI 2.8%-8.6%)。作者结论指出缺乏临床试验,汇总数据未显示未抗凝患者VTE复发或死亡率增加,提示临床均势,但受小样本、不精确和缺乏对照试验限制。

要点

  • 该系统评价纳入14项研究共15,563例患者,亚段肺栓塞汇总患病率为4.6%(95%CI 1.8%-8.5%)。
  • 抗凝组出血频率为8.1%(95%CI 2.8%-15.8%,n=589),未治疗组无出血数据(n=126)。
  • 90天内VTE复发:抗凝组5.3%(95%CI 1.6%-10.9%) vs 未抗凝组3.9%(95%CI 4.8%-13.4%)。
  • 死亡:抗凝组2.1%(95%CI 3.4%-5.2%) vs 未抗凝组3.0%(95%CI 2.8%-8.6%)。
  • 作者认为亚段肺栓塞抗凝或不抗凝存在临床均势,但受小样本、不精确和缺乏对照试验限制。

适用人群与场景

  • 有症状、接受计算机断层肺动脉造影且有足够信息确定亚段肺栓塞的患者。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析;从1,512篇文献中纳入14项研究共15,563例患者。
  • 汇总数据异质性I2=99%,Egger检验P<0.001,提示显著发表偏倚。
  • 亚段肺栓塞汇总患病率4.6%(95%CI 1.8%-8.5%)。
  • 抗凝组出血频率8.1%(95%CI 2.8%-15.8%,n=589),未治疗组无出血数据(n=126)。
  • 90天内VTE复发:抗凝组5.3%(95%CI 1.6%-10.9%) vs 未抗凝组3.9%(95%CI 4.8%-13.4%)。
  • 死亡:抗凝组2.1%(95%CI 3.4%-5.2%) vs 未抗凝组3.0%(95%CI 2.8%-8.6%)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入无对照的结局研究。
  • 局限:缺乏任何临床试验以就抗凝的伤害或获益做出明确推断;小样本、不精确、缺乏对照临床试验;异质性I2=99%;Egger检验P<0.001提示显著发表偏倚。

对床旁实践的改变

  • 作者认为亚段肺栓塞患者抗凝或不抗凝存在临床均势;该推断受小样本、不精确和缺乏对照临床试验限制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: This systematic review addresses the controversy over the decision to anticoagulate patients with subsegmental pulmonary embolism (SSPE).

METHODS: We searched Ovid MEDLINE, PubMed, Embase, the Cochrane Library, Scopus, Web of Science, ClinicalTrials.gov, Google Scholar, and bibliographies in March 2017. Two authors reviewed and retained papers with symptomatic patients who underwent computerized tomographic pulmonary angiography and had sufficient information to determine SSPE; decision to treat (or not) with systemic anticoagulation; and outcomes of bleeding, venous thromboembolism (VTE) recurrence, and death. Papers were assessed for selection and publication bias and heterogeneity, with Eggers and the inconsistency indexes (I2 ).

RESULTS: From 1,512 papers screened, we included 14 studies comprising 15,563 patients for full-length review and analysis. Pooled data demonstrated I2 = 99% with an Eggers p < 0.001, suggesting significant publication bias. The pooled prevalence of SSPE was 4.6% (95% confidence interval [CI] = 1.8%-8.5%). The frequency of bleeding in SSPE patients treated with anticoagulation (n = 589) was 8.1% (95% CI = 2.8%-15.8%), with no available bleeding data in untreated patients (n = 126). The frequency of VTE recurrence within 90 days was 5.3% (95% CI = 1.6%-10.9%) for treated versus 3.9% (95% CI = 4.8%-13.4%) for untreated, while the frequency of death was 2.1% (95% CI = 3.4%-5.2%) for treated versus 3.0% (95% CI = 2.8%-8.6%) for untreated.

CONCLUSION: This systematic review highlights the lack of any clinical trial to make a clear inference about harm or benefit of anticoagulation for SSPE. Comparison of pooled data from uncontrolled outcome studies shows no increase in VTE recurrence or death rates for patients who were not anticoagulated. These data suggest clinical equipoise for decision to anticoagulate or not anticoagulate patients with SSPE. However, this inference is limited by small numbers, imprecision, and the lack of a controlled clinical trial.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Bariteau A, Stewart LK, Emmett TW, et al. Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment. Acad Emerg Med. 2018. PMID: 29498138. doi:10.1111/acem.13399

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。